Tuberculosis Drug Discovery and Development 2019

• Format: eBook
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Subjects: anti-TB drug pipeline; anti-virulence compounds; antibiotic; antimicrobial drug resistance (AMR); antimycobacterial; antituberculosis agents; artificial pneumothorax; BCG; bedaquiline; Biology, life sciences; biomarkers; Carlo Forlanini; caseum; cell envelope; clinical studies; clinical trial; CTVD; delpazolid; discovery; DNA gyrase; dormancy; DprE1 inhibitor; drug combination; drug development; drug discovery; drug resistance; drug-drug interactions; EDCTP; electron transport chain; energy metabolism; genomics; granulomas; host-directed therapy; IAVI; in vitro; in vivo; isoniazid; lead generation; lipidomics; macozinone; Mathematics and Science; mechanism of action; mechanisms of resistance; metabolomics; MID3; mode of action; multi-drug resistance; mutations; mycobacteria; mycobacterium; Mycobacterium tuberculosis; n/a; oxidative phosphorylation; pharmacodynamics; pharmacokinetics; phenotypic screening; PknB; PknG; post-treatment sequelae; privileged targets; promiscuous targets; proteomics; pulmonary rehabilitation; Q203; Reference, Information and Interdisciplinary subjects; Research and information: general; rifampin; structure-based drug design; surgery; target; target identification; target-based drug design; target-based screening; TBVI; toxicity; transcriptomics; tuberculosis; tuberculosis treatment; tuberculosis vaccines

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main c...